Protection of Mice Against Fatal Herpes Simplex Type 2 Infection by Liposomes Containing Muramyl Tripeptide
- 26 April 1985
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 228 (4698) , 495-497
- https://doi.org/10.1126/science.2984772
Abstract
Intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine, a lipophilic derivative of muramyl dipeptide that activates macrophages to a cytolytic state in situ, significantly protected mice against lethal challenge with herpes simplex virus type 2. These findings suggest that the systemic activation of macrophages by liposomes containing an immunomodulator can lead to prophylaxis of severe infections caused by herpesviruses.This publication has 18 references indexed in Scilit:
- The potential use of liposome-mediated antiviral therapyAntiviral Research, 1985
- Human Monocytes Activated by Immunomodulators in Liposomes Lyse Herpesvirus-Infected But Not Normal CellsScience, 1984
- Immunomodulation by muramyl peptides: Recent developmentsClinical Immunology Newsletter, 1982
- Development of clinical resistance to acyclovir in herpes simplex virus-infected mice receiving oral therapyAntimicrobial Agents and Chemotherapy, 1982
- In vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomesCellular Immunology, 1981
- Macrophage Extrinsic Antiviral Activity during Herpes Simplex Virus InfectionJournal of General Virology, 1980
- Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouseInternational Journal of Immunopharmacology, 1979
- Multiple Range and Multiple F TestsPublished by JSTOR ,1955
- The use of the „studentized range” in connection with an analysis of varianceEuphytica, 1952
- THE DISTRIBUTION OF RANGE IN SAMPLES FROM A NORMAL POPULATION, EXPRESSED IN TERMS OF AN INDEPENDENT ESTIMATE OF STANDARD DEVIATIONBiometrika, 1939